Kyphon in Japan
This article was originally published in The Gray Sheet
Kyphoplasty study is first of its kind under Japan's new good clinical practice guidelines. Firm anticipates enrolling 80 patients at six centers, with enrollment expected to finish in 2006. Follow-up could extend for two years and will be bolstered with existing U.S. and European data to support an application for kyphoplasty in Japan. Japanese patients suffer from 500,000 vertebral compression fractures each year, according to Kyphon...
You may also be interested in...
Biopharma was an attractive investment in 2020 and fundamentals are unchanged in 2021, including the pandemic’s work-at-home requirements, which allowed more companies to go public faster.
Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.
While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.